Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.

Primary Sponsor

Australasian Gastro-Intestinal Trials Group (AGITG)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

50

Expected Date of Accrual

31 December 2026

Trial Chairperson

Dr Julie Chu, Peter MacCallum Cancer Centre, VIC, Australia

Trial Contact

qa@trog.com.au

Related Post

DECREASE trial into prostate cancer
8 July, 2025

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE

Geoff Zipper - aka Swamp - on the Kokoda Trail
26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

LATEST NEWS: 26 June 2025 He may be 76